Solicitar artículo | Melanoma Hub

Marca a continuación los artículos que te gustaría consultar:

Tafinlar Mekinist Eficacia *

Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis

Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients withUnresectable or Metastatic BRAF V600-Mutant Melanoma

Tafinlar Mekinist Seguridad *

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Retrospective Analysis of Safety in Elderly BRAF V600 mutation-positive Advanced Melanoma Patients treated with Dabrafenib (D) and Trametinib (T) and Correlation with Non-elderly Patients

Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma

Analysis of pirexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials

Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastasic and adjuvant setting

Seguridad de las combinaciones de inhibidores BRAF + MEK: evaluación de efectos adversos graves – Implicaciones en un entorno pos-COVID-19

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy

Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma

Tafinlar Mekinist en la Vida Real *

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)

Elderly patients (pts) with advanced melanoma: Results from the prospective real-world study GEM1801

Relation between Dabrafenib (D) plus Trametinib (T) induced pyrexia and age in braf V600 mutated metastatic melanoma patients: a post-hoc analysis of the real-world ELDERLYMEL study

General *

Follow‑up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus

Circulating Tumour DNA in Melanoma - Clinic Ready?

Real-World Adherence to Nodal Surveillance for Sentinel Lymph Node-Positive Melanoma

COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States

Survival Between Head and Neck Melanoma and Melanoma of Other Regions

Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts

Sex Differences in Cutaneous Melanoma: Incidence, Clinicopathological Profile, Survival, and Costs

Age Demographics of Subjects Enrolled in Global, Interventional Phase 3 Melanoma Clinical Trials

Hallmarks of Cancer: New Dimensions

Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions

Impacto de la pandemia SARS-CoV-2 en el diagnóstico precoz del melanoma

Conservación Mekinist: Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long-Term Storage at Room Temperature

Calidad de vida *

Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review

Patient preferences for treatment of advanced melanoma: impact of comorbidities

The Time Toxicity of Cancer Treatment

Secuenciación *

Comparison between first line target therapy and inmunotherapy in different prognostic categories of BRAF mutant metastatic melanoma patients

1044P – Sequential targeted and inmunotherapies in stage IV melanoma

Real World Sequencing Outcomes with Inmunotherapy and Targeted Therapy in BRAF+ Metastatic Melanoma (The NOBLE Study Series)

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Artículo suplementario del estudio DreamSeq

Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma

Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients

Triplete: Brazo DT+PBO *

*Spartalizumab no está aprobado para su uso en España. La adición de spartalizumab no ha demostrado mayor eficacia que la combinación de dabrafenib + trametinib.

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

Evaluating patients with a complete response in the Phase III COMBI-i study of spartalizumab or placebo plus dabrafenib and trametinib in patients with unresectable or metastatic cutaneous BRAF V600–mutant melanoma

Adyuvancia *

*Indicación no financiada para tratamiento adyuvante de melanoma: Dabrafenib en combinación con trametinib está indicado para el tratamiento adyuvante de pacientes adultos con melanoma con mutación BRAF V600 en Estadio III, tras una resección completa

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastasic and adjuvant setting

Three-years real-world evidence of adjuvant dabrafenib plus trametinib (DT) in patients with resected melanoma in Spain (GEM 1901 - DESCRIBE-AD)

Demography and clinical outcomes of adjuvant therapy in Spain: Results from GEM 1801 study

Por favor, rellena estos campos para completar la solicitud:

Nombre y apellidos:

(Incluir primer y segundo apellido)

Email:

Producto:

Patología:

Motivo de la consulta:

El Departamento Médico de Novartis Farmacéutica S.A. (“Novartis”) se compromete a proporcionar información científica precisa y equilibrada sobre sus productos.

Toda la información disponible en esta sección, o compartida con Ud. tras recibir su solicitud, está destinada únicamente a fines científicos no promocionales y puede contener información sobre productos o indicaciones actualmente en investigación y/o que aún no han sido aprobados por las autoridades reguladoras. Novartis facilita la información más reciente de la que tiene conocimiento, no obstante, no asume ninguna obligación de actualizar la información para reflejar acontecimientos posteriores.